Lung Cancer
Conditions
Keywords
smoking, cessation, mortality, quality of life
Brief summary
A large project consisting of: a) an observational trial where smoking status is recorded on 1400 consecutive people newly diagnosed with lung cancer. Smoking status is biologically validated with exhaled carbon monoxide (eCO) levels every 3 months. Survival, cancer progression and treatment complications will be recorded and compared in smokers, ex-smokers and never smokers.
Detailed description
Smoking causes around 85% of lung cancer. Continued smoking after diagnosis probably worsens survival and increases treatment complications but prospective well-designed studies are lacking. This project is an observational cohort study recording outcomes in smokers, never-smokers, and ex-smokers, using exhaled carbon monoxide to validate smoking status when they attend for further lung cancer clinics. This project is unique, as every patient with a clinical diagnosis of lung cancer will have their smoking status biologically validated by a quick and easy test, and those enrolled in the smoking cessation treatments or not will also complete a generic quality of life questionnaire at regular intervals. These appointments will coincide with other hospital appointments wherever possible, and survival status will reported up to 24 months after enrolment.
Interventions
None listed
Sponsors
Cardiff and Vale University Health Board
Dr Keir Lewis
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
* clinical diagnosis of lung cancer
Exclusion criteria
* refusal Consent * inability to provide exhaled CO * active psychiatric illness or substance misuse * concurrent malignancies of another type other than non-melanoma skin cancer * unable to travel for sessions with smoking cessation counsellor and / or outpatient visits from outset * WHO performance status 4 * Life expectancy less than 6 weeks.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Median and 2-year survival rates in confirmed smokers versus non- smokers newly diagnosed with lung cancer. | 24 months |
Secondary
| Measure | Time frame |
|---|---|
| Number of treatment complications in smokers versus non-smokers (frequency surgical wound complications, radiotherapy induced pneumonitis and median total radiation (Gy) dose; frequency and duration of neutropenic sepses | 2 years |
| Point prevalence of smoking at 0, 3, 6 12, 24 months | 2 years |
| Median survival and 2-year survival rates by smoking status for early (Stage I/II NSCLC) versus those with advanced (Stage III/IV) NSCLC. | 24 months |
| Accrual and attendance rates of lung cancer patients attending a hospital smoking cessation service | 2 years |
| Estimate of cost per quality adjusted life year gained by smoking cessation advice in both quit strategies for smokers | 2 years |
| Comparison of changes in health related quality of life (EQ5D) in smokers versus non-smokers | 2 years |
Countries
United Kingdom
Outcome results
None listed